Article Information
History
- August 20, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Emily C. Lydon1,*,†,
- Hoang Van Phan1,*,
- Eran Mick1,2,3,
- Natasha Spottiswoode1,
- Carolyn S. Calfee3,
- Peter M. Mourani4 and
- Charles R. Langelier1,2
- 1Division of Infectious Diseases, University of California, San Francisco, CA, USA
- 2Chan Zuckerberg Biohub San Francisco, San Francisco, CA, USA
- 3Division of Pulmonary and Critical Care Medicine, Cardiovascular Research Institute, University of California, San Francisco, CA, USA
- 4Department of Pediatrics, Section of Critical Care, University of Arkansas for Medical Sciences and Arkansas Children’s Hospital, Little Rock, AR, USA
- ↵†Corresponding Author:
Emily C. Lydon, 513 Parnassus Avenue, Room S380, San Francisco, CA 94143
↵* equal contributions
Contributions: CSC, PMM, CRL secured funding and designed and enrolled the clinical cohorts. ECL, CRL, PMM, CSC, and NS performed clinical adjudications for the cohorts. CRL performed RNA extractions and sequencing. EM, HVP, CRL, NS, and ECL conceived this specific project idea. HVP and EM performed data analysis and generated the figure. ECL, HVP, and CRL wrote the initial draft of the manuscript. All authors reviewed and approved the final manuscript.
Posted August 20, 2024.
Pulmonary FABP4 is an inverse biomarker of pneumonia in critically ill children and adults
